Content area
Abstract
Key messages * Argatroban can be considered as a safe therapeutic option in elderly patients with HIT and at high hemorrhagic risk, particularly in an ICU setting * In critically ill patients, the dosing of argatroban cannot be only adjusted with a global anticoagulation assay, aPTT * The use of aPTT in addition to anti-IIa measurement is essential for argatroban monitoring * The two methods, modified TT and ECT, used to measure anti-IIa activity, are not superimposable with higher values with TT compared with ECT Notes A comment to this article is available at http://dx.doi.org/10.1186/s13054-016-1196-6. Abbreviations ADR: adverse drug reaction AE: adverse event aPTT: activated partial thromboplastin time ARDS: acute respiratory distress syndrome BMI: body mass index DIC: dissiminated intravascular coagulation DTI: direct thrombin inhibitor DVT: deep vein thrombosis ECT: ecarin clotting time ELISA: enzyme-linked immunosorbent assay EOI: end of infusion FAS: full analysis set HIT: heparin-induced thrombocytopenia ICU: intensive care unit INR: international normalized ratio ISC: independent scientific committee MOF: multiple organ failure PAT: platelet aggregation PE: pulmonary embolism PP: per-protocol SAF: safety population SRA: serotonin release assay TEAE: treatment-emergent adverse event TT: thrombin time VKA: vitamin K antagonist Declarations Acknowledgements We thank the Scientific Committee composed of Meyer-Michel Samama, Thomas Lecompte and Bernard Tardy for their help with this research. J Crit Care. 2012;27:232-41.Google Scholar Hellwig TR, Peitz GJ, Gulseth MP. High-dose argatroban for treatment of heparin-induced thrombocytopenia with thrombosis: a case report and review of laboratory considerations.